Binding pockets [8]. Thus, imatinib is successful as a targeted therapy in GIST through inhibition of KIT or PDGFRA, and in other cancers, including Philadelphia chromosome-positive chronic myelogenous leukemias through inhibition of Bcr-Abl [9]. Clinical studies with imatinib have reported objective response rates of 50-70 and an estimated median survival of 57 months in patients with advanced G
What is Articlebase Social Networking SIte ?

Articlebase is an online social networking website here you can visit and generate quality backlinks, traffic for your website

Latest Comments